The objectives for this meeting will be as follows:

- To place the results of correlative biological studies in the context of ongoing care of patients in Canada with malignant disease and to translate these results into clinical practice;
- To provide a learning environment supportive to new investigators and to engage the academic pathology and research community in Canada in translational research initiatives associated with clinical trials;
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to the diagnosis, prognosis, treatment and adverse effects in the therapy of malignant disease;
- To update, review, and discuss recent results of translational studies conducted by or in collaboration with the NCIC Clinical Trials Group.

8:30 am  Welcome and Introductions  Ming Tsao
8:45 am  Update on TTDR activities, new infrastructure  Shakeel Virk
9:00 am  Update on Abstracts/Publications  Lois Shepherd
9:10 am  Update on CTRNet  Peter Watson
9:20 am  New NCTN Banking and Correlative Science Committees  Lois Shepherd
9:30 am  New Technologies (10 min each)
   - Circulating DNA/NGS  Scott Bratman
   - Nanostring Technology  David Scott/Torsten Nielsen
   - NGS/targeted sequencing  Suzanne Kamel-Reid
   - CALK A multi-centre biomarker testing standardization strategy  Ming Tsao
10:10 am  COFFEE
10:25 am  Reports from Disease Site Groups (5 min each)
   - GU  Kim Chi
   - Lung  Ming Tsao
   - Breast  Torsten Nielsen
- GI  Chris O’Callaghan
- Gyn  Anne Marie Mes-Masson
- Hem  Lois Shepherd
- IND Trials  Lois Shepherd

11:15  Strategic directions for Personalized Medicine/ Proposal for restructuring the CSTB  Ming Tsao

12:00 noon  Adjournment